Top

Published in:

01-03-2017 | Original Article

Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors

Authors: Shah-Jalal Sarker, Sophia K. Smith, Kashfia Chowdhury, Patricia A. Ganz, Sheryl Zimmerman, John Gribben, Ania Korszun

Published in: Supportive Care in Cancer | Issue 3/2017

Abstract

Purpose

The aims of this study were to examine quality of life, using the Impact of Cancer version 2 (IOCv2), in British non-Hodgkin lymphoma (NHL) survivors and investigate differences between survivors in the UK and the USA.

Methods

NHL survivors (326 UK and 667 US) completed the 37-item IOCv2 and psychological distress, fatigue and social support questionnaires.

Results

The IOCv2 showed good reliability in the British sample with higher internal consistency (Cronbach alpha 0.7–0.9) and no floor and ceiling effects. UK survivors showed significantly higher negative (p < 0.001) and higher positive (p = 0.003) IOC compared to US survivors. Younger survivors (p = 0.003), those with shorter time since diagnosis (p < 0.001) and with lower levels of social support (p = 0.001), showed more negative IOC in both groups. Higher negative IOC was also significantly associated with fatigue (p < 0.001) and depressive symptoms (p < 0.001) in both countries. Higher positive IOC was associated with female gender (p < 0.001), longer time since diagnosis (p = 0.02), those diagnosed at later stage (p < 0.05) and with greater social support (p = 0.004). Whereas significantly lower positive IOC was associated with white ethnicity (p < 0.001), higher education levels (p < 0.05) and fatigue (p = 0.001).

Conclusions

The IOCv2 is reliable and applicable in UK and US populations. Both negative and positive IOC scores were higher in British compared to US survivors. However, in both countries, psychosocial factors consistently showed the greatest impact on QOL irrespective of clinical characteristics. Recognition and treatment of individuals with these risk factors is a high priority for improving QOL in long-term cancer survivors, as is the development of modular interventions aimed at increasing positive IOC as well as decreasing negative impact. The IOCv2 shows great potential both as a screening and assessment measure for examining cancer-related outcomes among survivors.

Aziz NM (2009) Long-term cancer survivors: research issues and care needs in a key phase of the survivorship spectrum. Am J Hematol 84(12):782–784. doi:10.1002/ajh.21579 CrossRefPubMed

Leak A, Mayer DK, Smith S (2011) Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review. Leuk Lymphoma 52(6):972–985. doi:10.3109/10428194.2011.563884 CrossRefPubMedPubMedCentral

Ng AK (2011) Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 154(1):23–31. doi:10.1111/j.1365-2141.2011.08713.x CrossRefPubMed

National Cancer Survivorship Initiative Research Workstream: Priorities for reserch on cancer survivorship (2010) Department of Health, London, UK

Vissers PA, Thong MS, Pouwer F, Zanders MM, Coebergh JW, van de Poll-Franse LV (2013) The impact of comorbidity on health-related quality of life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv 7(4):602–613. doi:10.1007/s11764-013-0299-1 CrossRefPubMed

Zebrack BJ, Ganz PA, Bernaards CA, Petersen L, Abraham L (2006) Assessing the impact of cancer: development of a new instrument for long-term survivors. Psychooncology 15(5):407–421. doi:10.1002/pon.963 CrossRefPubMedPubMedCentral

Korszun A, Sarker SJ, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G, Matthews J, White P, Lister A, Gribben J (2014) Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol 164(6):790–803. doi:10.1111/bjh.12698 CrossRefPubMed

Rowlands IJ, Lee C, Janda M, Nagle CM, Obermair A, Webb PM, Australian National Endometrial Cancer Study G (2013) Predicting positive and negative impacts of cancer among long-term endometrial cancer survivors. Psychooncology 22(9):1963–1971. doi:10.1002/pon.3236 CrossRefPubMed

Ruiz F (2012) Acceptance and commitment therapy versus traditional cognitive behavioural therapy: a systematic review and meta-analysis of current empirical evidence. Int J Psychol Psychol Ther 12(2):333–357

10.

Crespi CM, Smith SK, Petersen L, Zimmerman S, Ganz PA (2010) Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors. J Cancer Surviv 4(1):45–58. doi:10.1007/s11764-009-0106-1 CrossRefPubMed

11.

Oerlemans S, Smith SK, Crespi CM, Zimmerman S, van de Poll-Franse LV, Ganz PA (2013) Assessing the impact of cancer among Dutch non-Hodgkin lymphoma survivors compared with their American counterparts: a cross-national study. Psychooncology 22(6):1258–1265. doi:10.1002/pon.3131 CrossRefPubMed

12.

Muzzatti B, Flaiban C, Romito F, Cormio C, Annunziata MA (2013) The Impact of Cancer Scale (IOC) in Italian long-term cancer survivors: adaptation and psychometric evaluation. Support Care Cancer 21(12):3355–3362. doi:10.1007/s00520-013-1909-1 CrossRefPubMed

13.

Dahl AA, Gudbergsson SB, Dorum A, Fossa SD, Liavaag AH, Sorebo O (2012) “The impact of cancer scale” version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors. Qual Life Res 21(8):1459–1470. doi:10.1007/s11136-011-0053-y CrossRefPubMed

14.

Hahn EE, Hays RD, Kahn KL, Litwin MS, Ganz PA (2015) Post-traumatic stress symptoms in cancer survivors: relationship to the impact of cancer scale and other associated risk factors. Psycho-Oncology 24(6):643–652. doi:10.1002/pon.3623 CrossRefPubMed

15.

Smith SK, Zimmerman S, Williams CS, Preisser JS, Clipp EC (2008) Post-traumatic stress outcomes in non-Hodgkin’s lymphoma survivors. J Clin Oncol 26(6):934–941. doi:10.1200/JCO.2007.12.3414 CrossRefPubMedPubMedCentral

16.

Hawkins MM, Lancashire ER, Winter DL, Frobisher C, Reulen RC, Taylor AJ, Stevens MC, Jenney M (2008) The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information. Pediatr Blood Cancer 50(5):1018–1025. doi:10.1002/pbc.21335 CrossRefPubMed

17.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370CrossRefPubMed

18.

Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP (1993) Development of a fatigue scale. J Psychosom Res 37(2):147–153CrossRefPubMed

19.

Mitchell PH, Powell L, Blumenthal J, Norten J, Ironson G, Pitula CR, Froelicher ES, Czajkowski S, Youngblood M, Huber M, Berkman LF (2003) A short social support measure for patients recovering from myocardial infarction: the ENRICHD Social Support Inventory. J Cardpulm Rehabil 23(6):398–403CrossRef

20.

Sherbourne CD, Stewart AL (1991) The MOS social support survey. Soc Sci Med 32(6):705–714CrossRefPubMed

21.

Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34–42. doi:10.1016/j.jclinepi.2006.03.012 CrossRefPubMed

22.

Cronbach L (1951) Coefficient alpha and the internal structure of tests. Psychometrica 16:287–334

23.

Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163. doi:10.1002/art.10993 CrossRefPubMed

24.

Smith SK, Zimmerman S, Williams CS, Benecha H, Abernethy AP, Mayer DK, Edwards LJ, Ganz PA (2011) Post-traumatic stress symptoms in long-term non-Hodgkin’s lymphoma survivors: does time heal? J Clin Oncol 29(34):4526–4533. doi:10.1200/JCO.2011.37.2631 CrossRefPubMedPubMedCentral

25.

Delgado-Sanz MC, Garcia-Mendizabal MJ, Pollan M, Forjaz MJ, Lopez-Abente G, Aragones N, Perez-Gomez B (2011) Heath-related quality of life in Spanish breast cancer patients: a systematic review. Health Qual Life Outcomes 9:3. doi:10.1186/1477-7525-9-3 CrossRefPubMedPubMedCentral

26.

Bourke L, Homer KE, Thaha MA, Steed L, Rosario DJ, Robb KA, Saxton JM, Taylor SJC (2013) Interventions for promoting habitual exercise in people living with and beyond cancer. Cochrane Db Syst Rev 9. doi:10.1002/14651858.CD010192.pub2

Title: Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors
Authors: Shah-Jalal Sarker
Sophia K. Smith
Kashfia Chowdhury
Patricia A. Ganz
Sheryl Zimmerman
John Gribben
Ania Korszun
Publication date: 01-03-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 3/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3454-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

A good death from the perspective of palliative cancer patients

Distress and psychological morbidity do not reduce over time in carers of patients with high-grade glioma

Return to work among breast cancer survivors: A literature review

Characteristics associated with inter-individual differences in the trajectories of self-reported attentional function in oncology outpatients receiving chemotherapy

Topical interventions to prevent acute radiation dermatitis in head and neck cancer patients: a systematic review

Effects of a multimodal rehabilitation programme on inflammation and oxidative stress in oesophageal cancer survivors: the ReStOre feasibility study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer